Cardio Diagnostics Holdings (CDIO) EBITDA (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted EBITDA of -$1.8 million for Q1 2026, down 21.98% sequentially from -$1.5 million in Q4 2025, and down 9.46% YoY from -$2.0 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) EBITDA (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported EBITDA for 6 years, with the latest figure at -$1.8 million in Q1 2026.
- Quarterly EBITDA fell 9.46% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.6 million (down 13.7% YoY) and the FY2025 annual result came in at -$6.5 million, up 22.49% from the prior year.
- EBITDA eased to -$1.8 million in Q1 2026 per CDIO's latest filing, from -$1.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$227094.0 in Q1 2022 and troughed at -$4.2 million in Q1 2024.
- A 5-year average of -$1.7 million and a median of -$1.5 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 198127.71% in 2022, then soared 60.79% in 2025.
- Over 5 years, EBITDA stood at -$2.4 million in 2022, then soared by 35.16% to -$1.5 million in 2023, then advanced by 1.66% to -$1.5 million in 2024, then gained by 3.51% to -$1.5 million in 2025, then slipped by 21.98% to -$1.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$1.8 million, -$1.5 million, and -$1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Mn |
| Mar 31, 2026 | -1.78 Mn |
| Dec 31, 2025 | -1.46 Mn |
| Sep 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.63 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -1.54 Mn |
| Sep 30, 2023 | -1.44 Mn |
| Jun 30, 2023 | -2.55 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -2.38 Mn |
| Sep 30, 2022 | -1.15 Mn |
| Jun 30, 2022 | -786,964.00 |
| Mar 31, 2022 | -227,094.00 |
| Dec 31, 2021 | -145,321.00 |
| Sep 30, 2021 | -721.00 |